Portola Pharmaceuticals

Based: South San Francisco
Stock symbol: PTLA
Range: $13 to $16
IPO price: $14.50
Close Oct. 17: $23.84
Change: Up 64%
Raised: $141 million

The scoop: Portola has been developing a pipeline of new therapies that can reverse the effect of Factor Xa inhibitors, or anticoagulants. And it has struck partnership deals with Pfizer ($PFE), Bristol-Myers Squibb ($BMY), J&J ($JNJ) and Bayer for their patients who experience an uncontrolled bleeding episode or are forced to undergo major surgery. With partners like that, Portola's pipeline, which includes the late-stage drug betrixaban, got a close-up from Wall Street when it filed its IPO back in April, a notable month for big S-1 filings for biotech companies. The stock priced in the mid-range, a solid success, raising a hefty $141 million. And shares continued to track north, adding to the company's market cap. Portola was named a Fierce 15 company back in 2009, after it had raised substantial venture backing. Those investments have been paying off big for the biotech's true believers.

For more:
Special report: 2009 Fierce 15 - Portola Pharmaceuticals
Portola rolls out $115M IPO plan as more biotech outfits go public
Portola partners with J&J, Bayer on blood thinner antidote
Portola raises $89M for late-stage betrixaban study

Portola Pharmaceuticals

Suggested Articles

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.

The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,